Shots:

• Alexion to get exclusive WW rights to develop and commercialize Elamipretide (SC) outside the US with an exclusive option to partner with Stealth for the development of Elamipretide based on P-III results in PMM. Stealth to receive up front $30M- option fee- an equity investment plus development funding
• If Alexion exercises the option- the companies will jointly co-promote Elamipretide in the US and will co-develop Elamipretide (SC) in the US for PMM- Barth syndrome and Leber’s hereditary optic neuropathy (LHON). Stealth to receive additional option exercise fee- an equity investment- development funding- regulatory & commercial milestone payments
• Elamipretide is a mitochondria-targeted therapeutic developed for primary mitochondrial myopathy (PMM) currently evaluated in P-III and has also received Fast Track and Orphan Designation for PMM- Barth syndrome and LHON

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Twitter